CFG Pharma SRL
CFG Pharma reported total assets of 50,919 € at the end of the 2025 financial year (annual accounts filed with the NBB on 03 Jun 2026).
The score of CFG Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -38 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
CFG Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jun 2026
- Year ended 31 Dec 2024filed on 25 Jun 2025
- Year ended 31 Dec 2023filed on 05 Jun 2024
- Year ended 31 Dec 2022filed on 19 Jun 2023
- Year ended 31 Dec 2021filed on 29 Aug 2022
CFG Pharma's financial analysis
- Solvency-407.2%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of CFG Pharma
CFG Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0746.821.410
- VAT number
- BE0746821410
- Peppol
- Registered · 0208:0746821410 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 11 May 2020
- Registered office
- 6180 Courcelles
- Latest accounts
- 2025 · filed on 03 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
CFG Pharma (SRL) has been based in Courcelles since 2020, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 28,517 € and equity of −207,337 €; its revenue is not published. Its solvency stands at -407.2%, below the median of its sector (46.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to CFG Pharma
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Evarmed Manufacture of basic pharmaceutical products Diepenbeek · balance sheet 51,346 €
- S-Form Pharma Manufacture of basic pharmaceutical products Etterbeek · balance sheet 20,430 €
- Calluna Pharma Manufacture of basic pharmaceutical products Hoogstraten · balance sheet 73,235 €
- Novozymatic Manufacture of basic pharmaceutical products Kapellen · balance sheet 148,440 €
- Harika Lifij Manufacture of basic pharmaceutical products Evere · balance sheet 105,370 €
- Xpert Protein Manufacture of pharmaceutical preparations Ghent · balance sheet 10,960 €
- RPO NucleoGenesis Manufacture of basic pharmaceutical products Ghent · balance sheet 107,514 €
Frequently asked questions about CFG Pharma
What is the revenue of CFG Pharma?
CFG Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of CFG Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0746821410 for CFG Pharma, if the company is VAT-registered. Its company number (CBE) is 0746.821.410.
Where is the registered office of CFG Pharma?
According to the CBE register, the registered office of CFG Pharma is in 6180 Courcelles.
What is the equity of CFG Pharma?
At the close of the 2025 financial year, the equity of CFG Pharma amounts to -207,337 €, a solvency of -407.2% of total assets.
Who manages CFG Pharma?
The register lists 6 active mandates at CFG Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of CFG Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →